We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Presence of Minor Anti Phospholipid Antibodies in Blood Samples of Ischemic Stroke Patients and Healthy Controls

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01487746
Recruitment Status : Unknown
Verified December 2011 by Meir Medical Center.
Recruitment status was:  Not yet recruiting
First Posted : December 7, 2011
Last Update Posted : December 7, 2011
Sheba Medical Center
Information provided by (Responsible Party):
Meir Medical Center

Brief Summary:

The investigators expect to find higher levels of both classical and minor antiphospholipid (APL) antibodies among the stroke cases. Furthermore, the investigators expect to find not only classical APLA but also minor antibodies.

The investigators believe that minor antibodies have a major role in the hypercoagulability state.

Condition or disease
Ischemic Stroke

Study Type : Observational
Estimated Enrollment : 207 participants
Observational Model: Case Control
Time Perspective: Prospective
Official Title: Presence of Minor Anti Phospholipid Antibodies in Blood Samples of Ischemic Stroke Patients and Healthy Controls.
Study Start Date : December 2011
Estimated Primary Completion Date : March 2012
Estimated Study Completion Date : September 2012

Stroke patients
healthy controls

Biospecimen Retention:   Samples Without DNA
Serum samples of Stroke patients withdrawned within 36 hrs since stroke evoked. Healthy controls

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
on a bank of 207 stroke patients serum samples, and also on 40 healthy controls. The samples were collected during the acute phase of the ischemic event.

Inclusion Criteria:

  • stroke diagnosis
  • blood sampling within 36hrs from the event
  • written agreement

Exclusion Criteria:

  • a stroke, MI or major operation prior to the current stroke
  • hypercoagulable state known in this patient
  • a severe chronic disease known at the time of the stroke
  • an infection on arrival (based on anamnesis, physical exam and lab tests)
  • thrombolytic treatment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01487746

Contact: Yair Levy, Prof. 0533671735 levy.yair@clalit.org.il,
Contact: Narin N Carmel, B.Sc 0547691482 carmeln@gmail.com

Meir health center Not yet recruiting
Kfar-saba, Israel
Sponsors and Collaborators
Meir Medical Center
Sheba Medical Center

Responsible Party: Meir Medical Center
ClinicalTrials.gov Identifier: NCT01487746     History of Changes
Other Study ID Numbers: 0125-11-MMC
First Posted: December 7, 2011    Key Record Dates
Last Update Posted: December 7, 2011
Last Verified: December 2011

Keywords provided by Meir Medical Center:
minor anti body
major anti body
APLA antibodies in Serum

Additional relevant MeSH terms:
Cerebral Infarction
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Pathologic Processes
Brain Infarction
Brain Ischemia
Antibodies, Antiphospholipid
Immunologic Factors
Physiological Effects of Drugs